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Abstract  
Low serum bilirubin concentrations are reported to be strongly associated with 
cardio-metabolic disease, but this relationship has not been reported among 
Indigenous Australian people who are known to be at high risk for diabetes and 
chronic kidney disease (CKD).   
Hypothesis: serum bilirubin will be negatively associated with markers of chronic 
disease, including CKD and anaemia among Indigenous Australians. 
Method: A cross-sectional analysis of 594 adult Aboriginal and Torres Strait 
Islander (TSI) people in good health or with diabetes and markers of CKD.  
Measures included urine albumin: creatinine ratio (ACR), estimated glomerular 
filtration rate (eGFR), haemoglobin (Hb) and glycated haemoglobin (HbA1c).  
Diabetes was defined by medical history, medications or HbA1c≥6.5% or 
≥48mmol/mol.  Anaemia was defined as Hb<130 g/L or <120 g/L in males and 
females respectively.  A multivariate regression analysis examining factors 
independently associated with log-bilirubin was performed.   
Results: Participants mean (SD) age was 45.1 (14.5) years, and included 62.5% 
females, 71.7% Aboriginal, 41.1% with diabetes, 16.7% with anaemia, 41% with 
ACR>3mg/mmol and 18.2% with eGFR<60ml/min/1.73m2.  Median bilirubin 
concentration was lower in females than males (6 v 8 µmol/L, p<0.001) and in 
Aboriginal than TSI participants (6 v 9.5 µmol/L, p<0.001).  Six factors explained 
35% of the variance of log-bilirubin; Hb and cholesterol (both positively related) 
and ACR, triglycerides, Aboriginal ethnicity and female gender (all inversely 
related). 
Conclusion: Serum bilirubin concentrations were positively associated with Hb and 
total cholesterol, and inversely associated with ACR.  Further research to 
determine reasons explaining lower bilirubin concentrations among Aboriginal 















Indigenous Australians have a higher burden of chronic non-communicable 
conditions, including anaemia, chronic kidney disease (CKD), diabetes and 
cardiovascular (CV) disease than other Australians [1].  Nationally reported 
statistics cannot adequately represent the variability within this population, 
including differences between the major indigenous ethnic groups (the Aboriginal 
and Torres Strait Islander peoples such as body composition or dyslipidaemia 
profile[2, 3]) or the geographical diversity with illness burden [4].  End stage 
chronic kidney disease is one chronic condition which disproportionately affects 
Indigenous Australian people than observed among non-Indigenous counterparts, 
occurring at a much younger age and for whom Indigenous females have almost 
twice the risk as Indigenous males [5].  It is recognised that additional mechanisms 
and markers of chronic disease risk are needed to explain the CV disease burden 
and risks within Indigenous Australian communities [6, 7].   
 
We recently reported an inverse association of total serum bilirubin (inclusive of 
the pathological range >20 µmol/L) with albumin to creatinine ratio (ACR) among 
participants of the eGFR Study [8], an adult Indigenous population living in diverse 
regions of Northern and Central Australia, stratified for good health, diabetes and 
CKD.  Serum bilirubin is the end product of haem degradation, has anti-oxidant 
properties, and in low concentration is associated with chronic cardio-metabolic 
disease risk [9].  Although our finding of an inverse association of ACR and bilirubin 
was consistent with reports of a cohort of adults with diabetes from Asia [10], it 
was in contrast to findings of a United States population-based health survey 
which reported a positive association between albuminuria and bilirubin [11].   
 
The prevalence and severity of anaemia within populations is an important health 
indicator [12].  Anaemia is a condition frequently reported among sub-populations 
of Indigenous Australians [13] and is associated with diabetes and chronic kidney 
disease [14].  Factors contributing to anaemia thus include poor quality diet, 
micronutrient absorption, the impact of anaemia related to co-morbid chronic 














negatively associated with markers of cardio-metabolic disease in Indigenous 
Australians, a population known to have high risk for anaemia, diabetes, 




Participants were self-identifying adult Aboriginal and Torres Strait Islander (TSI) 
Australians from the baseline eGFR Study [15], recruited from more than 20 sites 
in urban, regional and remote areas known to have a high background prevalence 
of dialysis-dependent end stage kidney (ESKD) disease.  All who expressed an 
interest to participate were able to be stratified for inclusion, including those with 
diabetes or CKD.  We excluded pregnant or breast feeding women, or participants 
with rapidly changing kidney function.  Participants provided written voluntary 
and informed consent for the eGFR Study, which received ethics approval and 
community support in each locality.  Ethics approval was provided by the Northern 
Territory Department of Health and Families and Menzies School of Health 
Research Human Research Ethics Committee, including the Indigenous ethics 
subcommittee, which has the power of veto over studies involving Indigenous 
Australian peoples.  Ethics approval for participants was provided in the other 
regions by the Cairns and Hinterland Health Services District Human Research 
Ethics Committee; Central Australian Human Research Ethics Committee; Western 
Australian Aboriginal Health Information and Ethics Committee; Royal Perth 
Hospital Ethics Committee. 
 
Measures 
Detailed descriptions of the methods have been previously described.  In brief, 
diabetes status was confirmed by the medical record or glycated haemoglobin 
(HbA1c) defined as ≥6.5% or ≥48mmol/mol [16]. Current smoking status was self-
reported and categorically described.  The  remoteness index score (ARIA) >10.53 
indicated a community/town in very remote Australia [17].  Medication 
prescription was recorded from participants and confirmed by the medical record.  














circumferences were collected [18]; waist to hip ratio (WHR) and body mass index 
(BMI) were calculated.  Laboratories local to each recruitment site measured (non-
fasting) serum high density lipoprotein (HDL)-cholesterol, C-reactive protein (CRP), 
HbA1c, urine albumin, urine creatinine  and serum creatinine was measured using 
an isotope dilution mass spectrometry traceable standardised assay.  During the 
period of this study, all Australasian laboratories achieved a coefficient of variation 
<15% for urine albumin (including 92% of participating laboratories achieving 
<10% .  These methods support less variation, and thus agreement of results 
across different platforms in urine albumin and creatinine (serum and urine) 
results.  Cystatin C was measured in a central laboratory as previously described 
[15, 19].  Estimated GFR (eGFR) was calculated by the chronic kidney disease 
epidemiology collaboration formula, without the African American correction 
factor [20].  Albuminuria was defined as ACR ≥3.0 mg/mmol [21].  Anaemia was 
defined as Hb<130 g/L in males and <120 g/L in females [12].  
 
Liver function tests including total serum bilirubin and haemoglobin were also 
performed in local laboratories.  Twelve laboratories used five individual methods 
for bilirubin across the recruitment sites (Ortho Clinical Diagnostics Fusion 5.1; 
Roche Cobas Integra 800; Roche Cobas Integra 400; Beckman Unicel DXc600; 
Ortho Clinical Diagnostics Vitros 250).  Detailed methods at each laboratory for 
these measures including total serum bilirubin have been previously described 
[15].  The total bilirubin method principle is diazo method having result 
traceability to the National Institute of Standards and Technology (NIST) Standard 
Reference Material (SRM) 916 across all the platforms, which minimises the 
variation of results between laboratories.  Standardisation of haemoglobin 
measurements are important [22], with methods standardised in Australia which 
minimises the variation of results between laboratories.  In this study, 
haemoglobin was analysed on the Beckman-Coulter analyser (HmX, MaxM, LH75, 
LH500), and Sysmex XE500, Abbott, Cell Dyne Saphire analysers. 
 
In this analysis, elevated serum total bilirubin was defined as >20µmol/L [23], and 














was categorically scored based on criteria described by Lee et al. [24] who defined 
liver disease as at least one of the following: alcohol excess, low serum albumin 
(<35 g/L), serum alanine transferase (ALT) twice the upper normal reference range 
(normal range: <44 mmol/L), serum total bilirubin twice the upper normal 
reference range (normal range <20 µmol/L).  Alcohol use was categorically 
recorded in the eGFR Study as follows: first, participants were asked about the 
frequency of alcohol consumed (daily, weekly, monthly and never), and second, on 
quantity of alcohol per reported frequency (1-7, 8-19, >20 units).  In this analysis 
alcohol excess was described if participants recorded daily alcohol consumption 
(no alcohol free-days)[25] or if weekly alcohol users consumed more than 20 units. 
 
This analysis describes 594 participants who had both a serum bilirubin and 
haemoglobin test result of the 653 participants enrolled at baseline, accounting 
for the following exclusions: age <18 years (n=13); missing data for haemoglobin 
(n=40), bilirubin (n=6) (Supplementary Figure S1).  Of the 600 participants with a 
Hb result, the first 29/600 participants only had a Hb result requested, whilst 
subsequent participants also had a mean corpuscle volume (MCV) available 
(n=568).  Using our crude criteria, 86/600 (14.3%) participants were identified with 
suspected liver disease as follows: daily alcohol consumption, high weekly alcohol 
consumers, serum ALT more than two times the upper limit of normal of 44 u/L, 
serum total bilirubin more than two times the upper normal limit of 20 µmol/L, 
and serum albumin less than 35g/L (n=16, 33, 10, 2 and 25 respectively).   
 
Statistical Analyses 
Descriptive characteristics of participants were reported by Indigenous status 
(Aboriginal or TSI) and, within each indigenous group, across tertiles of bilirubin.  
Categorical variables were described with a percentage and continuous variables, 
when normally distributed, with mean and standard deviation (SD). Continuous 
variables with a skewed distribution were described with median and interquartile 
range (IQR).  Serum bilirubin was also log-transformed to achieve a normal 














presented data for males and females separately with p values for trend in 
difference across tertiles of bilirubin by chi-squared test for categorical variables, 
(using heterogeneity test for continuous normally distributed variables and Kruskill 
Wallis test for continuous non-normally distributed variables.  Associations 
between participants’ characteristics and the outcome log-bilirubin were assessed, 
by first exploring the association of each independent factor with log-bilirubin.  
Subsequently we built multivariable models that included all the potentially 
significant factors (p<0.1 on linear regression models) and assessed the extent to 
which each model was effective at explaining the variability of the log-bilirubin by 
reporting the coefficient of determination (R2).  Sensitivity analyses exploring the 
impact of suspected liver disease was also explored.  Statistical analyses were 
performed using Stata v14 (Stata Corporation, College Station, TX).  
 
Results  
Diabetes, albuminuria (without significantly impaired eGFR) and hypertension 
were prominent findings observed among the 594 participants (Table 1). 
Aboriginal participants, who comprised 71% of the study cohort, had a higher 
frequency of anaemia, albuminuria and GFR<60 ml/min/1.73m2 than TSI 
participants.   
 
Bilirubin 
Serum total bilirubin had a non-normal distribution (skewed to the right), with a 
median (IQR); range) concentration of 6 (2, 29; range 2, 61) µmol/L.  Aboriginal 
participants had lower bilirubin concentrations than TSI participants (median 
(IQR): 6 (4, 8) µmol/L v 9.5 (7, 12) µmol/L, p=0.001).  Bilirubin concentrations were 
also lower in female than male participants (median (IQR): 6 (4, 8) µmol/L v 8 (6, 
11) µmol/L, p<0.001).  Logarithmic transformation of total serum bilirubin 
produced a normal distribution in values (Figure 1), with one unit change of log-
















Male participants, compared to females, had a higher mean (SD) Hb concentration 
(147 (15.7) g/L v 129.5 (15.6) g/L, p<0.001), and higher mean corpuscle volume 
(MCV) [86.5 (5.6) v 84.5 (6.6) fl, p=0.001].  Low MCV (<80 fl) was observed in 
17.2% of participants.  When anaemia was observed (in 100/600 participants), this 
was more frequently observed in females than males (17.9% v 12%, p=0.02), and 
was associated with a normal MCV (80-100 fl) in 58% and low MCV in 37% 
participants respectively.  The frequency of anaemia was almost twice as high in 
participants with diabetes than without diabetes (23.2% v 11.9%, p<0.001) and 
participants with lower eGFR [healthy with eGFR>90 ml/min/1.73m2 v Diabetes 
with eGFR≥90 ml/min/1.73m2 v GFR 60-89 ml/min/1.73m2 v eGFR 30-59 
ml/min/1.73m2 v eGFR<30 ml/min/1.73m2: 6.3 v 9.4 v 12.6 v 38.7 v 66.6%, 
p<0.001] respectively.   
 
We examined the characteristics of males and females separately by tertile of 
bilirubin (Table 2, 3).  Characteristics of males and females within tertile-1 
included a higher WHR, ACR, triglycerides, GGT and ALP (features of the metabolic 
syndrome) and lower Hb, lower MCV and lower serum albumin. There was a 
positive gradient of total cholesterol with tertile of bilirubin in both males and 
females.  Some differences in characteristics were noted between Aboriginal and 
TSI participants, and these are presented separately in each gender by tertile of 
bilirubin in supplementary Table S1 and S2.   
 
Regression modelling  
In unadjusted linear regression modelling among all participants, log-bilirubin was 
significantly and positively associated with: total cholesterol, Hb, MCV, ALT, 
cystatin C, triglycerides, remoteness index, and inversely associated with: ALP, 
albumin, ACE inhibitor-ARB use, statin use, urea, creatinine, ACR, diabetes, 
triglycerides, microscopic haemoglobinuria, WHR, total protein and aspirin use.  In 
the final multivariate regression model (Table 4), serum log-bilirubin was positively 
associated with Hb and total cholesterol and inversely associated with ACR and 
triglycerides, even after excluding participants with suspected liver disease (Figure 














ethnicity and serum triglycerides explained a higher proportion of the variance 
than ACR (12.6%, 2.3%, 1.1%). Conversely, haemoglobin concentration and total 
cholesterol were each positively associated with log-bilirubin (each explaining 
4.5% and 1.2%) of the explained variance of log-bilirubin.    
 
Discussion 
We report four key findings in this analysis of associations between bilirubin and 
the chronic conditions of diabetes, CKD and anaemia, in a cohort of 594 
Indigenous Australians recruited from more than twenty sites.  First serum log-
bilirubin was positively associated with haemoglobin concentration, and anaemia 
was also commonly observed in this cohort.  Second, log-bilirubin concentrations 
was positively associated with total cholesterol and inversely associated with 
triglycerides.  Third, the association between serum log-bilirubin and markers of 
chronic kidney disease was only observed for ACR, and not associated with other 
measures of kidney function that we assessed. Fourth, Aboriginal ethnicity was 
inversely associated with log-bilirubin, and explained the largest variance in the 
multivariate model, but the reasons for the lower bilirubin concentration than TSI 
participants remain unclear.  Low serum bilirubin concentration is a reported 
marker of oxidative stress and CV disease risk, and anaemia an important health 
indicator across populations [12].  Our findings demonstrate a strong association 
of bilirubin with heightened chronic disease risk in participants (particularly 
Aboriginal participants), though the causal link between bilirubin concentration 
and cardiovascular disease and other conditions is presently unknown in this 
population.   
 
Bilirubin is proportional to haemoglobin concentration 
Serum bilirubin was positively associated with haemoglobin concentration among 
participants, explaining 4.5% of the total variance in the multivariate regression 
model, and anaemia was also commonly observed in this cohort.  Anaemia was 
more frequently observed in participants with diabetes (in 23%) and lower eGFR 
(66% of adults with eGFR<30 ml/min/1.73m2), which is a relationship that is 














was suggestive of either anaemia of chronic disease, whilst the low MCV result 
was consistent with iron deficiency or potentially a thalassaemia trait [26].  It was 
not possible to further examine this without iron studies, dietary information, Hb 
electrophoresis or examine for intestinal parasites including strongyloidiasis [27], 
which is a prevalent condition associated with iron deficiency anaemia in this 
population, without information on the presence or absence of eosinophilia.  Lack 
of access to daily fruit and vegetables is an important modifiable contributor to 
cardiovascular disease in many populations [28], and in adults with CKD, 
uncorrected anaemia is strongly linked with the development of cardiovascular 
disease outcomes [29].  Our findings highlight the association between anaemia 
and adverse health among a cohort of Aboriginal and Torres Strait Islander adults 
recruited across a range of good health, diabetes and chronic kidney disease.   
 
Bilirubin & chronic disease risk associations 
Dyslipidaemia (including hyper-triglyceridaemia, low HDL cholesterol and  high 
non-HDL cholesterol) is an important cardiovascular disease risk marker [2, 9, 30] 
documented in both developed and developing countries internationally [28].  
Serum bilirubin levels have been associated with cardiovascular risk; hyper-
bilirubinaemia, such as occurs in Gilbert’s syndrome (a genetic mutation in the 
enzyme UGT1A which metabolises bilirubin) has been associated with lower 
cardiovascular disease risk, independent of the lipoprotein profile [31], and lower 
serum bilirubin concentrations are recognised as a marker of cardiovascular 
disease risk [9].  We hypothesised that serum bilirubin was associated with 
markers of chronic disease, including CV disease, CKD and anaemia among 
Indigenous Australians.  We have shown bilirubin was inversely associated with 
triglycerides, but bilirubin was also positively association with total cholesterol. 
We adjusted for numerous indicators of CV risk in the multivariate regression 
model by inclusion of age, blood pressure, adiposity, HbA1c, ACEI-ARB use, serum 
CRP and serum albumin.  Our finding of an inverse association between serum log-
bilirubin and triglycerides is consistent with other health screening surveys [32].  
Cardiovascular disease risk management guidelines promote reduction in total 














(statins) are reported to have a low negative effect on total bilirubin 
concentrations in individuals [34], however the final multivariate regression model 
was strengthened when limited to participants who were prescribed a statin.  We 
suggest reverse causality may be one explanation for the positive association 
between bilirubin and total cholesterol in this cross-sectional study.  Our findings 
remain unique, as other studies have not examined the association of bilirubin 
when adjusted for both Hb concentration and markers of CKD.   
 
Bilirubin and markers of chronic kidney disease  
This analysis explored more deeply the associations of albuminuria as part of its 
cardio-metabolic risk in this cohort [8].  Log-bilirubin was inversely associated with 
ACR in the multivariate regression analysis (coefficient -0.004, p=0.001), where 1 
mg/mmol higher ACR was associated with 0.004 units lower log-bilirubin, or 1.00 
µmol/L lower serum total bilirubin. In this cohort a wide range of ACR was 
observed (normo to macroalbuminuic range), thus ACR in the macroalbuminuria 
range is associated with lower bilirubin, and likely to be clinically meaningful.  Our 
finding of an inverse association of bilirubin and ACR was consistent with reports 
from Korea among adults with and without diabetes [35] and Taiwanese adults 
[24].  In contrast to our findings, we note the positive association between 
bilirubin and albuminuria among a United States study [11].  It is possible that 
these different associations between bilirubin and albuminuria may be explained 
by the clinical and biochemical characteristics of the cohorts, including differences 
in median bilirubin concentrations observed (United States cohort v our cohort: 
(median (IQR): 12(10.3-14.7) v 6(5, 9)µmol/L).   
 
In this analysis we have shown that bilirubin was not significantly explained by 
other measures of kidney function (Cystatin C, serum creatinine or eGFR).  Thus 
the association of low bilirubin was not likely to be explained by inhibiting effects 
of Cystatin C which has been shown to attenuate anti-inflammatory processes in 
the setting of low GFR [37].  We suggest the inverse association of serum total 
bilirubin and ACR more strongly reflects cardio-metabolic risk, since bilirubin was 















Riphagen et al. reported baseline bilirubin levels were inversely associated with 
both ACR and eGFR [38], however our analysis showed bilirubin was only inversely 
associated with ACR.  Our study findings remain important, since Riphagen et al. 
further reported low bilirubin concentration was associated with progression of 
diabetic kidney disease to ESKD, which has important implications for CKD and CV 
risk progression among Aboriginal and Torres Strait Islander peoples.  We 
acknowledge there are several factors of interest to bilirubin production in adults 
with chronic kidney disease (erythrocyte lifespan [39], albumin production, 
albumin-bilirubin binding, enzymatic degradation of haemoglobin in adults with 
renal disease [40]), which are unlikely to significantly explain low bilirubin 
concentrations, since our participants were recruited from the community without 
acute illness and had stable kidney function.   
 
Bilirubin concentrations between populations 
Our data shows Aboriginal participants had lower bilirubin values than TSI 
participants.  Reference ranges for bilirubin have not been developed from a 
healthy population of Aboriginal and Torres Strait Islander people, and there are 
very limited studies which describe the biochemical profiles including serum 
bilirubin of adult Indigenous Australians in very good health.  O’Dea et al. reported 
the following profile among a semi-traditionally living Aboriginal family group of 
18 adults in North-East Arnhem Land of the Northern Territory of Australia [41]: 
mean ((SD), range) serum bilirubin 5.6 ((0.3), 4-9) µmol/L, cholesterol 3.9 ((0.2), 
2.1-5.6) mmol/L, creatinine 80 ((10), 50-120) µmol/L and haematocrit 45.7 ((1.1), 
39-54) %, lean adult physique (BMI<17 kg/m2) [41].  Thus these bilirubin levels 
were not too dissimilar to values we herein report amongst a cohort with 
concurrent cardio-metabolic risks.   
 
It is unclear to what extent the different associations with bilirubin concentration 
and cardiovascular diseases reported across studies internationally (such as 
reported by Lee et al. [24] and Shin et al. [35]) were driven by ethnic population 














of bilirubin metabolism (haem-oxygenase, HO-1, and biliverdin reductase), genetic 
assessments were not measured in these studies.  Genetic variation studies 
(including mendelian randomisation) are one approach which may assist in 
addressing study confounding, to elucidate the causal relationships between gene 
products and outcomes.  A recent meta-analysis confirmed differences in HO-1 
genotype length between Asian and Caucasian populations, which the authors 
suggest are likely to impact on the interpretation of cardiovascular disease risk in 
large multiethnic studies[42].  Furthermore, by modelling the bilirubin gene 
UGT1A1*28, it was recently shown that bilirubin affects the cardiovascular system 
through vasomotor tone and artery reactivity [43].   
 
Weaknesses and Strengths 
We acknowledge some limitations in this study.  First we used a cross-sectional 
study design with volunteering participants, which introduces potential for bias 
and explores associations of low serum bilirubin and not causality.  Only serum 
total bilirubin was used in this analysis as we recognise that fractionated bilirubin 
measures are less clinically useful at low concentration of bilirubin.  Urine ACR was 
based on the assessment of a single urine sample.  Although all laboratories were 
nationally accredited, we acknowledge that differences in analytical methods for 
serum total bilirubin may make comparisons between laboratories difficult.  We 
did not undertake a sensitivity analysis for bilirubin concentration by laboratory or 
region as participants were not representative of all strata (or population 
representative) in all study sites, and thus not strata-representative in every 
laboratory catchment area.  In the multivariate regression model, the association 
of total bilirubin and total cholesterol (p=0.038) is regarded as borderline 
statistical significance given the number of tests performed.  Classification of 
adults with suspected liver disease may be enhanced by additional medical history 
(cirrhosis, viral hepatitis) and a detailed alcohol record [24].  We were unable to 
determine corroborating details of other factors which contribute to the balance 
of anti-oxidant and oxidant stress among participants including poor quality 
atherogenic diets low in micronutrients [28], physical inactivity, a comprehensive 














grade inflammation beyond the serum C-reactive protein [44].  These are often 
manifestations of communities in significant lifestyle transition and or poverty, 
thus disproportionately affecting minority and indigenous peoples in modernising 
countries [45, 46].  However, this study is unique as the only report describing the 
associations of serum bilirubin with metabolic risks in a community-based cohort 
of Aboriginal and or TSI people, and highlights modifiable associations of low 
serum bilirubin concentrations with ACR and low Hb concentration. 
 
Conclusions 
Our findings show that serum bilirubin is associated with markers of chronic 
disease, including CKD, dyslipidaemia, albuminuria and anaemia among 
Indigenous Australians.  Further work in this population is required to determine 
the normal range of bilirubin, including ascertainment of factors which may 
explain the lower bilirubin concentrations among Aboriginal participants; and 
prospectively determine any causal relationship of low serum bilirubin with 
chronic disease progression and evaluate bilirubin variance in response to 
targeted anaemia management.   
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Figure 1 Normal distribution curve of log bilirubin by gender and 
ethnicity.  Curves indicate (from left to right) Aboriginal female (solid), Aboriginal 

















Figure 2. Bilirubin concentration by anaemia and albuminuria group 
categories, which are fully adjusted for independent variables 
identified in the multivariate regression model. Bilirubin expressed as 















Table 1: Participant characteristics 
 
Aboriginal Ethnicity  72.1% 
Female sex  62.6% 
Diabetes 40.8% * 
Hypertension 42.3% *  
Anaemia 16.7% 
Albuminuria ⱡ 41.0 % * 
eGFR<60 ml/min/1.73m2 ⱡⱡ 18.0% 
ACEI-ARB use 34.3% 
Statin therapy use  25.6% 
Current Smoking 41.9% * 
Alcohol excess 33.9% *  
BMI >25 kg/m2 75.5% * 
Age, years 45.1 (14.5) 
eGFR⌠, ml/min/1.73m2  99.1 (79.5, 112.3)  
Cystatin C⌠ (mg/L) 0.85 (0.75, 1.01) * 
Urea⌠, mmol/L 4.8 (3.9, 6.5)  
ACR⌠, mg/mmol 1.8 (0.7, 19.6) * 
HbA1c⌠, mmol/mol 42.1 (37.7, 55.2) * 
Serum bilirubin⌠, µmol/L 6 (5,9)  
Serum albumin, g/L 42 (4)  
Hb, g/L 136 (18) 
MCV, fl 85.3 (6.3) * 
SBP, mmHg 118 (18) * 
DBP, mmHg 75 (10) * 
BMI, kg/m2 30.0 (7.2) * 
WHR  0.94 (0.09) * 
N=594.  Data are percentage, mean (standard deviation) or median (inter-
quartile range)⌠.  Data missing for* diabetes (n=593); hypertension (n=589); 
albuminuria (n=571); current smoking (n=585); alcohol excess (n=454); BMI 
(n=591); Cystatin C (n=545); ACR (n=571); HbA1c (n=588); MCV (n=562); 

















Table 2 Descriptive characteristics of male participants by bilirubin 
tertile  
 Bilirubin (µmol/L) N=222 
Tertile 1: 









  Percentage (%) 
Aboriginal ethnicity 222 89.6 72.2 39.0 <0.001 







Diabetes  222 51.2 30.6 29.7 0.007 














Alcohol excess  222 3.5  15.3 20.3 0.005 
Medication Prescription      
Statin 222 33.7 19.4 17.2 0.03 
Aspirin  222 38.4 13.9 17.2 <0.001 
ACEI-ARB  222 46.5 26.4 26.6 0.009 
  Mean (standard deviation) 
Age (years) 222 44.3 (13.6) 45.2 (16.6) 42.8 (16.0) 0.65 
BMI (kg/m
2




 30.0 (7.0) 0.03 







SBP (mmHg) 219 119 (19)
 Ɨ
 123 (17) 122 (16)
 Ɨ
 0.43 




























Alkaline phosphate (U/L) 221 109 (31) 97 (31)
 Ɨ
 90 (33) 0.001 
Serum albumin (g/L) 222 42 (5) 43 (4) 43 (5) 0.27 
Hb (g/L) 222 143 (17) 148 (14) 152 (14) 0.001 














  Median (interquartile range) 
Urea (µmol/L) 222 5.3 (4.4, 7.7) 5.6 (4.5, 7.2) 5.0 (4.2, 6.7) 0.51 
Creatinine (µmol/L) 222 86 (75, 116) 88 (73, 97) 82 (74, 93) 0.34 
eGFR (ml/min/1.73 m
2
) 222 96 (62, 109) 94 (78, 110) 100 (84, 114) 0.28 
Cystatin C (mg/L) 204 0.92 (0.78, 1.24)
 Ɨ
 0.86 (0.77, 1.07)
 Ɨ
 0.85 (0.75, 0.98)
 Ɨ
 0.08 
ACR (mg/mmol) 217 4.2 (1.0, 73.0)
 Ɨ
 1.4 (0.5, 15.0)
 Ɨ
 1.1 (0.6, 4.5)
 Ɨ
 0.001 
GGT (U/L) 222 51 (32, 81) 39 (27, 70) 30 (23, 50) 0.01 
ALT (U/L) 221 30 (22, 39) 33 (23, 43)
 Ɨ
 31 (22, 49) 0.45 
HbA1c (mmol/mol) 221 44.3 (39.9, 63.9)
 Ɨ
 41.5 (38.8, 47.5)
 
 40.4 (36.6, 48.6) 0.009 
Triglycerides (mmol/L) 217 2.2 (1.5, 3.3)
 Ɨ
 1.8 (1.5, 2.4)
 Ɨ
 1.6 (1.1, 2.3)
 Ɨ
 0.001 
CRP (mg/L) 215 5 (3, 10) 4 (2, 8)
 Ɨ




 Data incomplete as follows: Tertile 1, n=85 [smoking , BMI, WHR, SBP, DBP, total protein, HbA1c]; n=84 [Very remote 
residence, ACR, CRP]; n=83 [total cholesterol, Hct, MCV, triglycerides]; n=82 [HDL-cholesterol]; N=81 [urine 
microhaemoglobinuria]; N=78 [Cystatin C]. Tertile 2, n=71 [Very remote residence, smoking, BMI, SBP, DBP, total 














micro-haemoglobinuria]; n=65 [Cystatin C]. Tertile 3, n=63 [smoking, urine microhaemoglobinuria, total cholesterol, Hct, 

















Table 3 Descriptive characteristics of female participants by bilirubin 
tertile  
Bilirubin (µmol/L) N=372 
Tertile 1: 






8-29 µmol/L  
n=118 
p 
  Percentage (%) 
Aboriginal  372 92.6 73.6 47.5 <0.001 







Diabetes  371 49.1 41.8 33.3
 Ɨ
 0.03 














Excess alcohol  372 2.5 4.4 11.0 0.008 
Medication Prescription      
Statin 372 35.6 13.2 23.7 <0.001 
Aspirin  372 24.5 17.6 22.0 0.44 
ACEI-ARB  372 42.3 31.9 25.4 0.01 
  Mean (standard deviation) 
Age (years) 372 45.3 (14.6) 46.5 (12.8) 44.8 (14.3) 0.70 
BMI (kg/m
2
) 371 30.9 (7.4) 
Ɨ
  29.9 (6.6) 30.4 (7.6)  0.58 







SBP (mmHg) 369 118 (18) 
Ɨ
 118 (17) 113 (18) 
Ɨ
 0.07 
DBP (mmHg) 369 75 (9)
 Ɨ
 76 (10)  72 (9)
 Ɨ
 0.005 




 5.0 (1.2) 
Ɨ
 0.001 












Alkaline phosphate (U/L) 372 115 (42) 102 (34) 100 (45) 0.004 
Serum albumin (g/L) 372 41 (4) 42 (4) 42 (4) 0.02 
Hb (g/L) 372 125 (17) 131 (13) 135 (13) <0.001 














  Median (interquartile range) 
Urea (µmol/L) 372 4.6 (3.7, 9.0) 4.6 (3.7, 5.9) 4.8 (3.9, 5.7) 0.51 
Creatinine (µmol/L) 372 63 (54, 97) 57 (52, 66) 62 (56, 72)  <0.001 
eGFR (ml/min/1.73 m
2
) 372 97 (55, 115) 106 (94, 114) 99 (87, 112)  0.03 
Cystatin C (mg/L) 341 0.85 (0.73, 1.44) 
Ɨ
 0.82 (0.72, 0.97) 
Ɨ
 0.82 (0.76, 0.92) 
Ɨ
 0.09 
ACR (mg/mmol) 354 2.9 (0.9, 53.5) 
Ɨ
 2.2 (0.9, 13.5) 
Ɨ
 1.1 (0.6, 4.2) 
Ɨ
 <0.001 
GGT (U/L) 372 33 (23, 62) 
Ɨ
 31 (25, 46) 26 (19, 41)  0.03 
ALT (U/L) 371 23 (17, 30) 
Ɨ
 23 (17, 30) 24 (18, 37)  0.24 
HbA1c (mmol/mol) 367 43.2 (38.3, 158.5)
 Ɨ
 43.2 (38.8, 55.2) 
Ɨ
 39.9 (36.6, 49.7) 
Ɨ
 0.03 
Triglycerides (mmol/L) 363 2.1 (1.4, 2.7) 162 1.7 (1.3, 2.3) 
Ɨ
 1.5 (1.0, 1.9) 
Ɨ
 <0.001 
CRP (mg/L) 364 7 (4, 15) 159 6 (3, 12) 
Ɨ
 5 (2.3, 10) 
Ɨ
 0.01 
For current smokers; bilirubin data is expressed as geometric mean (95% confidence interval). Ɨ Data incomplete as follows: Tertile 1, 
n=162 [current smoking, BMI, total cholesterol, triglycerides, ALT]; n=161 [SBP, DBP]; n=160 [HbA1c]; n=159 [Very remote residence, 
CRP]; 158 [HDL-cholesterol]; n=151 [Hct, MCV, ACR]; n=150 [WHR, urine microhaemoglobinuria]; n=144 [Cystatin C]. Tertile 2, n=90 
[total protein, HbA1c, CRP]; n=88 [Very remote residence, current smoking, ACR]; n=87 [urine micro-haemoglobinuria, total 














DBP, HbA1c]; n=116 [Very remote residence, current smoking, Cystatin C]; n=115 [WHR, ACR, CRP]; n=114 [total cholesterol, 
















Table 4 Multivariate regression model of log-bilirubin 
 
 
Model A: All Participants 
 Model B: Participants without 













Aboriginal ethnicity -0.43 -0.51 -0.35 <0.001  -0.42 -0.50 -0.33 <0.001  
Female -0.10 -0.18 -0.02 0.02  -0.12 -0.21 -0.03 0.011  
Hb (g/L) 0.010 0.007 0.012 <0.001  0.008 0.005 0.011 <0.001  
ACR (mg/mmol) -0.0004 -0.0007 -0.0002 0.001  -0.0004 -0.0007 -0.0001 0.004  
Triglycerides (mmol/L) -0.06 -0.09 -0.04 <0.001  -0.07 -0.10 -0.03 <0.001  
Cholesterol 0.04 0.002 0.072 0.038  0.055 0.018 0.092 0.004  
ALT 0.002 0.0001 0.004 0.038  - - - -  
Constant 0.89 0.53 1.25 <0.001  1.02 0.63 1.41 <0.001  
 Model R2 0.39,  n=556  Model R
2 0.35,  n=479 
The initial model included categorical variables (1=Yes, 0=No) [Female sex, Aboriginal ethnicity, Diabetes, very 
remote residence, microscopic haem, medications (statin, aspirin, ACEI-ARB)] and continuous variables [WHR, 
triglycerides, total cholesterol, total protein, alkaline phosphatase, alanine transferase, serum albumin, 
haemoglobin, mean cell volume, urea, creatinine, eGFR, cystatin C, ACR].  Log-bilirubin was converted to 
bilirubin (in µmol/L) using bilirubin =exp(equation). 
Model B: Thus bilirubin = exp[(1.02 -0.42(if Aboriginal) -0.12 (if female) + 0.008 (Hb) -0.0004 (ACR) -0.07 




















 Bilirubin was positively associated with Hb and inversely associated with ACR 
 Bilirubin was not associated with other markers of kidney function apart from ACR 
 Bilirubin was lower in Aboriginal than Torres Strait Islander participants 
 Factors explaining this lower concentration requires further investigation 
ACCEPTED MANUSCRIPT
